PSK8 IMPACT OF ATOPIC DERMATITIS ON THE QUALITY-OF-LIFE OF PARENTS OF CHILDREN WITH ATOPIC DERMATITIS
Arnold RJG 1 , Zhou Y 1 , Wong KS 2 , Sung J 2 1 Pharmacon International, Inc, New York, NY, USA; 2 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA OBJECTIVES: Atopic dermatitis (AD) is a common childhood chronic skin condition. Despite high disease prevalence, up to 20% in some populations, little information is available regarding the burden of disease to children and parent/caregivers. An objective of this study was to assess the impact of AD on parents'/caregivers' quality-of-life. METHODS: In total, 414 AD patients, between 2-12 years old were identified through a retrospective review of outpatient billing records from January, 2001 to December, 2004 from two large physician practices and were contacted to enroll in the study. Data collected included patient demographics, comorbidities, treatments, and health care resource use. Parents also completed the Parent's Index of Quality of Life-Atopic Dermatitis (PIQoL-AD), a 28-item, validated questionnaire evaluating parents' needs-based quality-oflife. Total PIQoL-AD scores can range from zero to 28, with a higher score indicating greater impaired quality-of-life. One-way analysis of variance was used to determine statistical significance. RESULTS: Mean patient age was 6.7 (SD ± 3.3) years and 55% of patients were males. Mean duration and treatment of illness were 3.0 ± 2.2 years and 20.7 ± 21.4 months, respectively. Parents' assessment of disease severity indicated that 82% of patients had mild AD and 13% of patients had moderate AD. Patients reporting at least one flare experienced 2.8 ± 2.3 flares per month; mean duration of flares was 5.2 ± 7.0 days. Disease flares negatively impacted parents' quality-of-life. PIQoL-AD scores worsened among those parents whose child had disease flares. Mean PIQoL-AD scores were statistically significantly higher (5.9 ± 5.4 vs. 3.0 ± 3.6, p < 0.0001) for those parents whose child had disease flares compared to those who did not have disease flares. CONCLUSIONS: Study findings will improve our understanding of the impact of AD on children and their parents/caregivers and may enhance treatment effects, clinical outcomes, and patient and parent/caregiver education. Further investigation is needed to understand the impact of atopic dermatitis on parents' quality-of-life.
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PREVALENCE OF CHRONIC HAND DERMATITIS AND ITS IMPACT ON PATIENT-REPORTED OUTCOMES IN A MANAGED CARE POPULATION
Fowler JF 1 , Duh MS 2 , Chang J 3 , Ghosh A 2 , Sung J 4 , Emani S 5 , Den E 2 , Thorn D 4 , Person J 6 1 University of Louisville, Louisville, KY, USA; 2 Analysis Group, Inc, Boston, MA, USA; 3 Duke Clinical Research Institute, Durham, NC, USA; 4 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; 5 Fallon Clinic, Worcester, MA, USA; 6 Fallon Clinic, Auburn, MA, USA OBJECTIVES: The prevalence of chronic hand dermatitis (ChHD) and its impact on patient-reported outcomes, including quality of life (QoL), work and activity impairment, were evaluated in a managed care organization (MCO). To date, few studies have investigated ChHD using a general populationbased approach. METHODS: A validated cross-sectional patient-reported survey was mailed to 1380 members of a Massachusetts MCO. The survey consisted of: a 13-item clinical questionnaire identifying ChHD based on signs and symptoms of dermatitis related to hands, treatment response, and diagnoses of exclusion; the Skindex-29, a 29-question dermatology-specific QoL instrument; and the Work Productivity and Activity Impairment (WPAI) instrument validated for ChHD. Those receiving the survey were randomly sampled from the general MCO population and a subset population with ≥ two medical claims with a dermatitis or eczema diagnosis (ICD-9 692 or 691.8). ChHD patients were compared to patients with other skin conditions and to Non-ChHD patients to assess their relative QoL and WPAI measures, respectively. RESULTS: Based on the survey respondents (36.7% response rate), the prevalence of ChHD was 17.5% in the MCO general population, a rate much higher than previously found (2-12%). QoL and WPAI measures for the ChHD patients were significantly worse than those for their comparison groups (Skindex score: ChHD = 30.33 ± 17.51, Other Skin Conditions = 20.05 ± 16.68; Work Impairment: ChHD = 29.33%, Non-ChHD = 6.85%; Activity Impairment: ChHD = 33.78%, Non-ChHD = 17.32%; all p < 0.0001).
